R 0005/22 of 24.11.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:R000522.20221124
- Date of decision
- 24 November 2022
- Case number
- R 0005/22
- Petition for review of
- -
- Application number
- 14172398.1
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Controlled release pharmaceutical compositions comprising a fumaric acid ester
- Applicant name
- FWP IP APS
- Opponent name
- ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
G. L. Pharma GmbH
Strawman Limited
Zentiva k.s.
Hexal AG
Laboratorios Liconsa, S.A.
Interquim S.A.
Biogen MA Inc.
Actavis Group PTC EHF
Generics [UK] Limited
STADA Arzneimittel AG - Board
- -
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112a(2)(c)European Patent Convention Art 113(1)European Patent Convention Art 123(2)European Patent Convention Art 76(1)European Patent Convention R 106
- Keywords
- Violation of right to be heard (no)
"surprise" reasoning in decision (no) - no causal link to decision (obiter dictum) - point 6 reasons - Catchword
- -
- Cited cases
- R 0016/13
- Citing cases
- R 0008/19
Order
For these reasons it is decided that:
The petition for review is unanimously rejected as being clearly unallowable.